2015
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate
Gueorguieva R, Wu R, Tsai WM, O’Connor P, Fucito L, Zhang H, O’Malley S. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology 2015, 25: 1586-1599. PMID: 26141511, PMCID: PMC4600651, DOI: 10.1016/j.euroneuro.2015.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAcamprosateAdultAlcohol DeterrentsAlcoholismBody Mass IndexDecision TreesDouble-Blind MethodHumansMiddle AgedTaurineTreatment OutcomeUnited StatesConceptsAcamprosate effectHeavy drinkingShort abstinenceEnhanced treatment responseMonths of treatmentSubgroup of patientsBody mass indexDrug plasma levelsIdentification of subgroupsBetter prognosisLower BMIMass indexPlasma levelsGlutamatergic hyperactivityTreatment responseAcamprosateCOMBINE StudyPrior treatmentLarger studyConsecutive daysAbstinencePretreatment abstinenceTreatment effectsCognitive inefficiencySubgroups
2000
Thrice-weekly versus daily buprenorphine maintenance
Schottenfeld R, Pakes J, O’Connor P, Chawarski M, Oliveto A, Kosten T. Thrice-weekly versus daily buprenorphine maintenance. Biological Psychiatry 2000, 47: 1072-1079. PMID: 10862807, DOI: 10.1016/s0006-3223(99)00270-x.Peer-Reviewed Original ResearchConceptsSublingual buprenorphineMaintenance treatmentSelf-reported illicit drug useDrug useOpioid agonist maintenance treatmentOpioid-positive urine testsAgonist maintenance treatmentDaily clinic attendanceDaily sublingual buprenorphineThrice-weekly dosingOpioid-dependent patientsUrine toxicology testsSignificant differencesIllicit drug useSelf-reported numberBuprenorphine maintenanceClinic attendanceWeekly doseIllicit opioidsMedication complianceThrice weeklyUrine testsOutcome measuresBuprenorphineCounseling attendance
1999
Plasma concentrations of buprenorphine 24 to 72 hours after dosing
Chawarski MC, Schottenfeld RS, O’Connor P, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug And Alcohol Dependence 1999, 55: 157-163. PMID: 10402160, DOI: 10.1016/s0376-8716(98)00192-6.Peer-Reviewed Original ResearchConceptsDose scheduleWithdrawal symptomsPlasma concentrationsDaily buprenorphine doseHigh-dose scheduleThrice-weekly scheduleAdministration of buprenorphineOpiate-dependent subjectsHigher plasma concentrationsUse of heroinBuprenorphine doseDaily administrationOutpatient clinicPlasma levelsSublingual administrationAgonist effectsOpiate useHeroin useLow doseHigh doseBuprenorphine solutionMg/70High dosesConcentration 24Dependent subjects
1997
Three methods of opioid detoxification in a primary care setting. A randomized trial.
O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals Of Internal Medicine 1997, 127: 526-30. PMID: 9313020, DOI: 10.7326/0003-4819-127-7-199710010-00004.Peer-Reviewed Original ResearchConceptsPrimary care settingOpioid detoxificationCare settingsBuprenorphine groupWithdrawal symptomsDouble-blind clinical trialOpioid-dependent patientsHeroin-dependent patientsPrimary care clinicsWithdrawal symptom scoresSevere withdrawal symptomsDrug treatment programsSubstance abuse treatmentNaltrexone groupCare clinicsSymptom scoresPharmacologic protocolClinical trialsTreatment protocolClonidineTreatment retentionBuprenorphineNaltrexoneTreatment programAbuse treatmentSustained-release methylphenidate for cognitive impairment in HIV-1- infected drug abusers: a pilot study
van Dyck CH, McMahon TJ, Rosen MI, O'Malley SS, O'Connor PG, Lin CH, Pearsall HR, Woods SW, Kosten TR. Sustained-release methylphenidate for cognitive impairment in HIV-1- infected drug abusers: a pilot study. Journal Of Neuropsychiatry 1997, 9: 29-36. PMID: 9017526, DOI: 10.1176/jnp.9.1.29.Peer-Reviewed Original ResearchMeSH KeywordsAdultAttentionCentral Nervous System StimulantsCognition DisordersDelayed-Action PreparationsDouble-Blind MethodFemaleHIV InfectionsHIV-1HumansLearningMaleMemoryMethylphenidateMiddle AgedNeuropsychological TestsOpioid-Related DisordersPilot ProjectsPsychomotor PerformanceSubstance-Related DisordersConceptsSustained-release methylphenidateCognitive impairmentDouble-blind placebo-controlled crossover trialPlacebo-controlled crossover trialComposite neuropsychological measuresImpaired neuropsychological test performanceClinical improvementPlacebo treatmentCrossover trialMethadone patientsNeuropsychological test performancePlacebo performancePsychostimulant drugsDrug abusersPatientsStudy designPilot studySubstance abusersImpairmentNeuropsychological measuresMethylphenidateMore improvementAbusersTreatmentTest performanceTreatment of Early AIDS Dementia in Intravenous Drug Users: High Versus Low Dose Peptide T
Kosten T, Rosen M, McMahon T, Bridge T, O'malley S, Pearsall R, O'connor P. Treatment of Early AIDS Dementia in Intravenous Drug Users: High Versus Low Dose Peptide T. The American Journal Of Drug And Alcohol Abuse 1997, 23: 543-553. PMID: 9366972, DOI: 10.3109/00952999709016894.Peer-Reviewed Original Research